

Elena Shagisultanova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7845823/publications.pdf>

Version: 2024-02-01

10
papers

184
citations

1478505

6
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

309
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. <i>Gene</i> , 2015, 567, 1-11.	2.2	57
2	Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 369-382.	2.5	36
3	Issues in interpreting the <i>in vivo</i> activity of Aurora-A. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 187-200.	3.4	20
4	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-11.	1.2	19
5	<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	3.0	17
6	Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 694-704.	3.4	13
7	Overall survival is the lowest among young women with postpartum breast cancer. <i>European Journal of Cancer</i> , 2022, 168, 119-127.	2.8	10
8	Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 48-57.	4.1	6
9	Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 216-226.	1.0	5
10	Abstract P1-17-01: Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide. <i>Cancer Research</i> , 2022, 82, P1-17-01-P1-17-01.	0.9	1